MC-38 Cell Line

MC-38 Cell Line derived from C57BL6 murine colon adenocarcinoma cells.

From the laboratories of James W. Hodge, PhD, MBA and Jeffrey Schlom, PhD, National Cancer Institute/NIH.

Catalog Number Product Size AVAILABILITY Price Qty
ENH204
MC-38 Cell Line
1 vial In stock
Price: $733.00

This product is for sale to Nonprofit customers only. For profit customers, please Contact Us for more information.

Specifications
Product Type: Cell Line
Name: MC-38
Organism: C57BL6 murine
Accession ID: CVCL_B288
Morphology: Epithelial
Biosafety Level: BSL2
Subculturing: 1:5 to 1:10
Growth Conditions: Dulbecco's modified MEM with 10% fetal bovine serum, 2mM glutamine, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 10 mM Hepes, 50ug/ml gentamycin sulfate, pen/strep.
Cryopreservation: 90% FBS, 10% DMSO
Source: Colon Carcinoma
Mycoplasma Tested: Yes; Also tested for mouse pathogens (See: MC-38 Pathogen Testing Results)
Storage: Liquid nitrogen
Shipped: Dry ice
Provider

hodge, PhD

James W. Hodge, PhD, MBA
National Cancer Institute/NIH

References
  1. Roh-Johnson M, Shah AN, Stonick JA, Poudel KR, Kargl J, Yang GH, di Martino J, Hernandez RE, Gast CE, Zarour LR, Antoku S, Houghton AM, Bravo-Cordero JJ, Wong MH, Condeelis J, Moens CB. Macrophage-Dependent Cytoplasmic Transfer during Melanoma Invasion In Vivo. Dev Cell. 2017 Dec 4;43(5):549-562.e6. View Article
  2. Obermajer N, Urban J, Wieckowski E, Muthuswamy R, Ravindranathan R, Bartlett DL, Kalinski P. Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents. Nat Protoc. 2018 Feb;13(2):335-357. View Article
  3. Xiao Q, Wu J, Wang WJ, Chen S, Zheng Y, Yu X, Meeth K, Sahraei M, Bothwell ALM, Chen L, Bosenberg M, Chen J, Sexl V, Sun L, Li L, Tang W, Wu D. DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med. 2018 Mar;24(3):262-270. View Article
  4. Villarreal DO, L'Huillier A, Armington S, Mottershead C, Filippova EV, Coder BD, Petit RG, Princiotta MF. Targeting CCR8 induces protective antitumor immunity and enhances vaccine-induced responses in colon cancer. Cancer Res. 2018 Jul 19. pii: canres.1119.2018. View Article

If you publish research with this product, please let us know so we can cite your paper.

 
Loading...
Loading...